No Data
Morgan Stanley Maintains Acelyrin(SLRN.US) With Hold Rating, Maintains Target Price $5
Morgan Stanley Maintains Acelyrin(SLRN.US) With Hold Rating, Cuts Target Price to $5
Hold Rating Maintained for ACELYRIN, INC. Amidst Izokibep Study Setback and Revised Sales Projections
Acelyrin Price Target Lowered to $5 From $6 at Morgan Stanley
ACELYRIN Is Maintained at Overweight by Wells Fargo
Wells Fargo Maintains Overweight on Acelyrin, Lowers Price Target to $13
AW138 : thank you sir, always appreciate your posts
DaTrader AW138 : I second that
WILLEE9ice : tons of thanks master, you have has done the jobs
Jenna Ragan : Thank you kindly
Tottigol10 : I can't understand unfortunately..any recommendations on where i can start to study and get more into it?
View more comments...